{
    "id": "0816",
    "question": "A 65-year-old woman comes to the physician for a routine bone mineral density screening. She does not have any children. Menopause was at age 55. Her mother died of breast cancer at the age of 48 years. She has hypertension for which she takes ramipril. Dual-energy x-ray absorptiometry at the femoral neck shows a T-score of -2.7 SD. The physician considers treatment with raloxifene. This medication would put her at increased risk of developing which of the following conditions?",
    "options": {
        "A": "Pulmonary embolism",
        "B": "Cellulitis",
        "C": "Breast cancer",
        "D": "Hypercholesterolemia"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"The patient is a 65-year-old postmenopausal woman with a T-score of -2.7 SD at the femoral neck, indicating osteoporosis. Raloxifene is a selective estrogen receptor modulator (SERM) that is often prescribed for the prevention and treatment of osteoporosis in postmenopausal women. SERMs like raloxifene have estrogen agonist effects on some tissues, such as the uterus and bones, and antagonist effects on others, such as the breasts and cardiovascular system. Given this dual action, the primary concern with raloxifene is its potential to increase the risk of breast cancer, which is a known side effect of estrogen therapy. The patient's family history of breast cancer (mother died of breast cancer at age 48) may also increase her risk. The other options are not directly related to the primary concern with raloxifene treatment in this context. Pulmonary embolism is not a known side effect of raloxifene, cellulitis is not related to SERM use, and hypercholesterolemia is not a common side effect of raloxifene.\", \"answer_choice\": \"C\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 14.883718967437744
}